Pelthos Therapeutics Inc (PTHS)

$23.12 +0.71 (3.17%)
Market Cap 74.81M
Revenue (ttm) 0.00
Net Income (ttm) -7.96M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 2,600
Avg Vol 12,348
Day's Range N/A - N/A
Shares Out 3.24M
Stochastic %K 15%
Beta 3.87
Analysts Strong Sell
Price Target $58.00

Company Profile

Pelthos Therapeutics Inc., a bio-pharmaceutical company, develops and commercializes therapeutic products to help patients with unmet treatment burdens. The company offers ZELSUVMI for the treatment of molluscum contagiosum in adults and children 1 year of age and older. It also provides NITRICIL, a proprietary nitric oxide-based technology platform. The company was formerly known as Channel Therapeutics Corporation and changed its name to Pelthos Therapeutics Inc. in July 2025. Pelthos Therapeu...

Industry: Biotechnology
Sector: Healthcare
Phone: 877 265 8266
Website: pelthos.com
Address:
4020 Stirrup Creek Drive, Suite 110, Durham, United States
Revempire
Revempire Mar. 8 at 5:43 AM
$ALDX The PDUFA (Prescription Drug User Fee Act) action date is March 16, 2026. $PTHS The company is estimated to report its next quarterly earnings around June 3, 2026
1 · Reply
twib
twib Feb. 27 at 6:23 PM
$PTHS Still taking advantage,imo, of sp under $30. Nice of them to keep it reasonably priced at the earliest stages of zelsvi prescriptions growth. See they still have a pelthos of open sales positions in US.
0 · Reply
notreload_ai
notreload_ai Feb. 27 at 4:11 PM
Piper Sandler starts $PTHS at Overweight, PT $48; sees Zelsuvmi driving >$200M peak U.S. sales in underserved market. https://notreload.xyz/analyst-bullish-on-pelthos-therapeutics-big-potential-in-skin-treatment/
0 · Reply
Jwa68
Jwa68 Feb. 27 at 1:20 PM
$PTHS Nice initiation by Piper Sandler with a $48 target. Will post some notes later. Big deal getting these guys to launch coverage.
0 · Reply
ChopSeeker
ChopSeeker Feb. 20 at 4:55 PM
$PTHS Pelthos Therapeutics develops dermatology treatments. Clinical validation is required. Early-stage risk is high.
0 · Reply
Jwa68
Jwa68 Feb. 20 at 1:59 PM
$PTHS 620 units...they are executing.
1 · Reply
Jwa68
Jwa68 Feb. 18 at 6:56 PM
$PTHS With M&A heating up in the space amd larger pharma seeing so many patented assets lose their protection and exclusivity, there's a real likelihood a bigger company may want to take these guys out with the valuation upside and their potential.
0 · Reply
Jwa68
Jwa68 Feb. 18 at 6:52 PM
$PTHS Pretty mispriced currently, trading about 4 times net revenue, despite a successful product launch with growing revenue and two additional, highly complementary FDA approved products being launched later this year and early next year.
0 · Reply
Jwa68
Jwa68 Feb. 18 at 6:49 PM
$PTHS Appears as though they have seen an increase from 361 units for the week ending 1/2/26 to 560 units the week ending 2/6/26.
0 · Reply
ReversalKnight
ReversalKnight Feb. 10 at 2:23 PM
$PTHS is a biotech or pharmaceutical company; name not standard, indicating high risk.
0 · Reply
Latest News on PTHS
Horizon Technology Finance Provides up to $50 Million Venture Loan Facility to Pelthos Therapeutics

Jan 15, 2026, 4:10 PM EST - 7 weeks ago

Horizon Technology Finance Provides up to $50 Million Venture Loan Facility to Pelthos Therapeutics

HRZN

Pelthos Therapeutics Secures Up to $50 Million Senior Secured Term Loan Facility from Horizon Technology Finance

Jan 13, 2026, 8:30 AM EST - 7 weeks ago

Pelthos Therapeutics Secures Up to $50 Million Senior Secured Term Loan Facility from Horizon Technology Finance

Pelthos Therapeutics Acquires Xeglyze® (abametapir) Topical Treatment for Head Lice

Jan 5, 2026, 7:30 AM EST - 2 months ago

Pelthos Therapeutics Acquires Xeglyze® (abametapir) Topical Treatment for Head Lice

Pelthos Pharmaceuticals: Off To A Strong Start With Zelsuvmi, Continued Sales Growth Is Likely

Dec 1, 2025, 6:34 PM EST - 3 months ago

Pelthos Pharmaceuticals: Off To A Strong Start With Zelsuvmi, Continued Sales Growth Is Likely

Pelthos Therapeutics Inc. (PTHS) Q3 2025 Earnings Call Transcript

Nov 13, 2025, 3:11 PM EST - 4 months ago

Pelthos Therapeutics Inc. (PTHS) Q3 2025 Earnings Call Transcript

Pelthos Therapeutics Announces Third Quarter Fiscal 2025 Financial Results

Nov 13, 2025, 6:45 AM EST - 4 months ago

Pelthos Therapeutics Announces Third Quarter Fiscal 2025 Financial Results

Pelthos Therapeutics Acquires Xepi® (ozenoxacin) Cream, 1% and Announces $18 Million Private Convertible Notes Financing

Nov 7, 2025, 8:00 AM EST - 4 months ago

Pelthos Therapeutics Acquires Xepi® (ozenoxacin) Cream, 1% and Announces $18 Million Private Convertible Notes Financing

Pelthos Therapeutics to Report Third Quarter 2025 Financial Results on November 13, 2025

Nov 5, 2025, 8:00 AM EST - 4 months ago

Pelthos Therapeutics to Report Third Quarter 2025 Financial Results on November 13, 2025

Pelthos Therapeutics to Participate in Upcoming September Investor Conferences

Sep 8, 2025, 8:30 AM EDT - 6 months ago

Pelthos Therapeutics to Participate in Upcoming September Investor Conferences

Pelthos Therapeutics Reports Second Quarter 2025 Financial Results for Legacy Operations and Provides Business Update

Aug 18, 2025, 8:00 AM EDT - 7 months ago

Pelthos Therapeutics Reports Second Quarter 2025 Financial Results for Legacy Operations and Provides Business Update

Revempire
Revempire Mar. 8 at 5:43 AM
$ALDX The PDUFA (Prescription Drug User Fee Act) action date is March 16, 2026. $PTHS The company is estimated to report its next quarterly earnings around June 3, 2026
1 · Reply
twib
twib Feb. 27 at 6:23 PM
$PTHS Still taking advantage,imo, of sp under $30. Nice of them to keep it reasonably priced at the earliest stages of zelsvi prescriptions growth. See they still have a pelthos of open sales positions in US.
0 · Reply
notreload_ai
notreload_ai Feb. 27 at 4:11 PM
Piper Sandler starts $PTHS at Overweight, PT $48; sees Zelsuvmi driving >$200M peak U.S. sales in underserved market. https://notreload.xyz/analyst-bullish-on-pelthos-therapeutics-big-potential-in-skin-treatment/
0 · Reply
Jwa68
Jwa68 Feb. 27 at 1:20 PM
$PTHS Nice initiation by Piper Sandler with a $48 target. Will post some notes later. Big deal getting these guys to launch coverage.
0 · Reply
ChopSeeker
ChopSeeker Feb. 20 at 4:55 PM
$PTHS Pelthos Therapeutics develops dermatology treatments. Clinical validation is required. Early-stage risk is high.
0 · Reply
Jwa68
Jwa68 Feb. 20 at 1:59 PM
$PTHS 620 units...they are executing.
1 · Reply
Jwa68
Jwa68 Feb. 18 at 6:56 PM
$PTHS With M&A heating up in the space amd larger pharma seeing so many patented assets lose their protection and exclusivity, there's a real likelihood a bigger company may want to take these guys out with the valuation upside and their potential.
0 · Reply
Jwa68
Jwa68 Feb. 18 at 6:52 PM
$PTHS Pretty mispriced currently, trading about 4 times net revenue, despite a successful product launch with growing revenue and two additional, highly complementary FDA approved products being launched later this year and early next year.
0 · Reply
Jwa68
Jwa68 Feb. 18 at 6:49 PM
$PTHS Appears as though they have seen an increase from 361 units for the week ending 1/2/26 to 560 units the week ending 2/6/26.
0 · Reply
ReversalKnight
ReversalKnight Feb. 10 at 2:23 PM
$PTHS is a biotech or pharmaceutical company; name not standard, indicating high risk.
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Feb. 5 at 1:04 AM
$PTHS RSI: 44.31, MACD: -0.6430 Vol: 1.52, MA20: 24.91, MA50: 25.61 🔴 SELL - Downtrend 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
DeadInvestor
DeadInvestor Jan. 26 at 10:41 PM
$PTHS @Jwa68 Any luck getting scripts updates? would love to see trend of last ~8 weeks.
1 · Reply
DeadInvestor
DeadInvestor Jan. 17 at 3:11 PM
$PTHS @Jwa68 Any scripts update?
1 · Reply
Jwa68
Jwa68 Jan. 13 at 7:42 PM
$PTHS Good news and continued execution by management.
0 · Reply
twib
twib Jan. 9 at 11:54 PM
$PTHS Def not for those with little conviction! Lol
0 · Reply
twib
twib Jan. 7 at 8:28 PM
$PTHS Still not ready for 30+. Loading weekly when possible
0 · Reply
garygb
garygb Jan. 3 at 6:48 PM
$PTHS Bottom feeder selection.
0 · Reply
DARKP00L
DARKP00L Jan. 2 at 10:03 PM
$PTHS 16:52 on Jan. 02 2026 On Dec 23, Pelthos Therapeutics Enters Asset Purchase Agreement With Hatchtech; Hatchtech Sells Rights To Xeglyze Product To Co. For $1.8M #tradeideas
0 · Reply
Jwa68
Jwa68 Dec. 31 at 9:53 PM
$PTHS Nice day.
1 · Reply
mateo86
mateo86 Dec. 31 at 9:18 PM
$PTHS not a bad jump to end the year!!
0 · Reply
DeadInvestor
DeadInvestor Dec. 29 at 10:18 AM
$PTHS @Jwa68 Any update on scripts numbers Jwa68?
0 · Reply
SuperGreenToday
SuperGreenToday Dec. 26 at 11:24 AM
$PTHS
1 · Reply